2026· [Rinsho ketsueki] The Japanese journal of clinical hematology· Vol 67 8, pp.
934-939
· 0 citations
Medicine
TL;DR
This case suggests that a multidisciplinary treatment strategy incorporating TBF conditioning may improve relapse-free survival in patients with BP-MPN.
The data suggest that alloSCT can be effective after CART failure, with more than one-third of patients being in remission after two years, and these findings support the continued use of alloSCT in patients with aggressive lymphomas.
A. O. Saidy, B. Altmann, P. van Heteren et al.· Haematologica· 0 citations
8 Gy TBI-Bu-Flu with PTCy is a feasible reduced-radiation conditioning platform, providing reliable engraftment and encouraging leukemia control with no NRM in pediatric high-risk or relapsed ALL, however, the GVHD incidence was higher than anticipated, indicating that the prophylaxis backbone should be optimized in fu...
J. Yoo, Suejung Jo, Seongkoo Kim et al.· Transplantation and Cellular...· 0 citations
A review of the current concepts of post-transplant maintenance therapy in AML/MDS discusses emerging evidence supporting MRD-guided treatment strategies and molecularly targeted maintenance approaches, highlighting future perspectives for optimizing relapse prevention after allo-HSCT.
Y. Najima· [Rinsho ketsueki] The Japane...· 0 citations
It is suggested that a higher-dose anti-CD25, methotrexate-free prophylactic approach may reduce acute GVHD and improve GRFS after haplo-HSCT, while its effects on long-term disease control and survival require confirmation in multicenter randomized trials.
Qian-Lin Liu, Ao Zhang, Hong-Ru Chen et al.· Haematologica· 0 citations
It is suggested that, within a treosulfan–PTCy platform, major transplant outcomes are comparable between donor types, although haploidentical transplantation was associated with a higher incidence of chronic GVHD.
D. Avenoso, M. Farina, M. Malagola et al.· American journal of hematolo...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.